期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 98, 期 3, 页码 235-241出版社
WILEY
DOI: 10.1111/ejh.12821
关键词
splenectomy; immune thrombocytopenia; chronic; adult
类别
资金
- National Natural Science Foundation of China [81270581, 81300385, 81470286]
- Tianjin Municipal Science and Technology Commission [14JCZDJC35100]
- Specialized Research Fund for the Doctoral Program of Higher Education [20131106120039]
ObjectivesWe performed this study in adult patients with chronic primary immune thrombocytopenia to explore the long-term efficacy and safety of splenectomy. MethodsData of 174 patients who underwent splenectomy in our hospital from 1994 to 2014 were analyzed. ResultsAfter splenectomy, 126 (72.4%) patients achieved a complete response (CR) and 28 (16.1%) achieved a response (R). Thirty-two (20.8%) responders relapsed with a median time of 24 months. Compared with non-responders and recurrent patients, the stable responders were younger and had higher preoperation and postoperation peak platelet count, later peak platelet count emergence time, and more megakaryocytes. Corticosteroid-dependent patients were more likely to response to splenectomy than those refractory to corticosteroid. We performed a relapse-free survival analysis among the 154 responders. In univariate analyses, corticosteroid dependent and time from diagnosis to splenectomy 24 months showed predictive value to persistent response. But only corticosteroid dependent was a significant predictor in multivariate analysis. The 30-d complication rate after the surgery was 25.9%. There were five (2.9%) patients experienced thrombosis and three (1.7%) refractory patients died during follow-up. ConclusionsSplenectomy was a safe treatment with a cure rate of 58.0%. Corticosteroid dependent showed predictive value to persistent response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据